Becton, Dickinson and Co. (NYSE:BDX) will unveil its latest earnings on Tuesday, February 7, 2012. The average estimate of analysts is for profit of $1.17 per share, a decline of 13.3% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from $1.18. Between one and three months ago, the average estimate moved down. It has been unchanged at $1.17 during the last month. For the year, analysts are projecting net income of $5.79 per share, a rise of 3% from last year.
Last quarter, the company saw profit of $1.39 per share versus a mean estimate of net income of $1.39 per share. This comes after two consecutive quarters of exceeding expectations. On average, analysts predict $1.88 billion in revenue this quarter, a rise of 2.2% from the year ago quarter. Analysts are forecasting total revenue of $7.99 billion for the year, a rise of 2% from last year’s revenue of $7.83 billion.
Competitors to Watch: Covidien plc (NYSE:COV), Thermo Fisher Scientific Inc. (NYSE:TMO), C.R. Bard, Inc. (NYSE:BCR), Teleflex Incorporated (NYSE:TFX), Retractable Tech., Inc. (AMEX:RVP), Hologic, Inc. (NASDAQ:HOLX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Medical Action Industries (NASDAQ:MDCI), Quidel Corporation (NASDAQ:QDEL), and Gen-Probe Incorporated (NASDAQ:GPRO).
Cerner Corp (NASDAQ:CERN) will unveil its latest earnings on Tuesday, February 7, 2012. The average estimate of analysts is for profit of 50 cents per share, a rise of 22% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged. It also has not changed during the last month. Analysts are projecting profit to rise by 25.2% versus last year to $1.74.
Last quarter, the company saw net income of 45 cents per share versus a mean estimate of profit of 45 cents per share. This comes after two consecutive quarters of exceeding expectations. Analysts are projecting a rise of 17.3% in revenue from the year-earlier quarter to $586.8 million.
Competitors to Watch: Allscripts Healthcare Solutions Inc (NASDAQ:MDRX), Mediware Info. Systems (NASDAQ:MEDW), CareFusion Corporation (NYSE:CFN), Quality Systems, Inc. (NASDAQ:QSII), Merge Healthcare Inc. (NASDAQ:MRGE), McKesson Corporation (NYSE:MCK), Streamline Health Solutions Inc. (NASDAQ:STRM), Aspyra Inc. (APYI), Omnicell, Inc. (NASDAQ:OMCL), and Computer Sciences Corp. (NYSE:CSC).
To contact the reporter on this story: Derek Hoffman at email@example.com
To contact the editor responsible for this story: Damien Hoffman at firstname.lastname@example.org